YD Bio Limited

Contributing Author

Recent Articles by YD Bio Limited

Apr-30	YD Bio Limited Reports Full Year 2025 Financial Results YDES -5.88% YDES GlobeNewswire
Mar-31	YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States YDES GlobeNewswire
Mar-17	YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem YDES -8.55% GlobeNewswire
Feb-25	YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform YDES GlobeNewswire
Jan-29	YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy YDES -9.89% GlobeNewswire
Jan-06	YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation-Driven AI Platforms for Cancer Diagnostics and Drug Development YDES -8.04% GlobeNewswire
Jan-05	YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap YDES +5.67% GlobeNewswire
Dec-16	YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center YDES GlobeNewswire
Dec-09	YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN YDES -18.42% GlobeNewswire
Dec-02	YD Bio Limited Expands OkaiDx Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection YDES GlobeNewswire
Nov-24	YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics YDES GlobeNewswire
Nov-05	YD Bio and EG BioMed Expand U.S. Access to OkaiDx, a cfDNA-Methylation Blood Test for Post-Treatment Breast Cancer Monitoring YDES GlobeNewswire
Oct-20	YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES YDES GlobeNewswire
Oct-10	YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities YDES -6.95% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)